Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
Cancer Letters
|
July 11, 2012
Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals
Inke Lühr, Andreas Friedl, Thorsten Overath, et al.
Breast Cancer Research and Treatment
|
April 27, 2012
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management
Simone Heidemann, Christine Fischer, Christoph Engel, et al.
Oncology
|
August 30, 2014
Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer
Nicolai Maass, Christian Schem, Dirk O Bauerschlag, et al.
Onkologie
|
April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system
Michael P Lux, Achim Wöckel, Agnes Benedict, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2017
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Ian Smith, Denise Yardley, Howard Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Yingyao Zhou, et al.
Oncogene
|
November 24, 2004
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Felix Hilpert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2010
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial
Michael Untch, Michael Muscholl, Sergei Tjulandin, et al.
Plos One
|
October 12, 2012
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer
Antonia Sophie Wenners, Keyur Mehta, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
Manfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
Cancer Letters
|
July 11, 2012
Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals
Inke Lühr, Andreas Friedl, Thorsten Overath, et al.
Breast Cancer Research and Treatment
|
April 27, 2012
Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management
Simone Heidemann, Christine Fischer, Christoph Engel, et al.
Oncology
|
August 30, 2014
Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer
Nicolai Maass, Christian Schem, Dirk O Bauerschlag, et al.
Onkologie
|
April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system
Michael P Lux, Achim Wöckel, Agnes Benedict, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2017
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Ian Smith, Denise Yardley, Howard Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Yingyao Zhou, et al.
Oncogene
|
November 24, 2004
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
Ivo Meinhold-Heerlein, Dirk Bauerschlag, Felix Hilpert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2010
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial
Michael Untch, Michael Muscholl, Sergei Tjulandin, et al.
Plos One
|
October 12, 2012
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer
Antonia Sophie Wenners, Keyur Mehta, Sibylle Loibl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
Manfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Page
of 11